Zoldonrasib clinical trials
Also written RMC-9805.
How each study uses zoldonrasib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zoldonrasib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Daraxonrasib (3) · Gemcitabine (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Elironrasib (1) · Cetuximab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test zoldonrasib.
- Dec 2026Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsPhase 1 · Revolution Medicines, Inc.
- Jun 2027Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCPhase 1/2 · Revolution Medicines, Inc.
Studies
Open first, then newest update. How each study uses zoldonrasib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )RecruitingPhase 3Revolution Medicines, Inc.NCT07621718Written as Zoldonrasib
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07805954Written as zoldonrasib
- Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCRecruitingPhase 3Revolution Medicines, Inc.NCT07777822Written as zoldonrasib
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingPhase 1/2Revolution Medicines, Inc.NCT06162221Written as RMC-9805
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT06445062Written as RMC-9805
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsRecruitingPhase 1Revolution Medicines, Inc.NCT06040541Written as RMC-9805
Given beside what is tested · 2 — zoldonrasib is usual care or a partner of the new treatment
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT07397338Written as Zoldonrasib
- Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsRecruitingPhase 1/2Tango Therapeutics, Inc.NCT06922591Written as RMC-9805
Codes
What other systems call zoldonrasib · ClinicalTrials.gg INT018469
- UNII (FDA) XJ52BWK3XEZOLDONRASIBOne source FDA
- NCI Thesaurus C201828ZoldonrasibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | XJ52BWK3XE | ZOLDONRASIB | One source FDA |
| NCI Thesaurus | C201828 | Zoldonrasib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.